Biotech advances investigational therapy for acute postoperative pain and highlights cross-sector leaders supporting its mission
DARIEN, CT, UNITED STATES, October 13, 2026 /EINPresswire.com/ — Cytogel Pharma, a clinical-stage biopharmaceutical company focused on endomorphin-based pain treatments, has confirmed that patient enrollment is now active for its Phase 2 study of CYT-1010.
The push for a novel approach to managing moderate to severe pain that balances efficacy with safety has galvanized a broad coalition of patients, caregivers, clinicians, researchers, and advocates. Because pain touches individuals across every age group and stems from a wide array of conditions, injuries, and surgical interventions, the call for fresh scientific and clinical momentum has never been more urgent.
CYT-1010, the company’s flagship investigational compound, is being developed specifically for acute postoperative pain of moderate to severe intensity. The ongoing Phase 2 trial is structured to assess both the efficacy and safety of CYT-1010 in patients recovering from surgery, with top-line data anticipated in the first quarter of 2027. The therapy employs a distinctive mechanism centered on mu-opioid receptor biology, making it the pioneer candidate from Cytogel’s endomorphin-based platform to reach the clinical stage.
“We are frequently reminded that behind every experience with pain is a person with their own story,” said C. Dean Maglaris, Chief Executive Officer of Cytogel Pharma. “As our Phase 2 clinical trial of CYT-1010 moves forward, we remain focused on rigorous research and the development of a potential new option for patients recovering from surgery. This milestone reflects years of scientific work and brings us closer to understanding CYT-1010’s potential significant role in pain management.”
Guiding Cytogel’s efforts is a leadership roster that spans medicine, science, public policy, behavioral health, and patient advocacy. The company’s Board of Directors and Board of Advisors feature the Honorable Chris Christie, former Governor of New Jersey and past Chairman of the President’s Commission on Combating Drug Addiction and the Opioid Crisis; the Honorable Patrick J. Kennedy, former U.S. Congressman and founder of The Kennedy Forum; Jerry Leamon, Chairman of the Board of Directors for Korn Ferry and former Global Managing Director of Deloitte; Mike Ullmann, former Executive Vice President and General Counsel at Johnson and Johnson; and Fred Telling, PhD, former Corporate Vice President of Pfizer.
These varied perspectives, combined with input from Cytogel’s scientific and clinical advisors, help steer the company’s overarching commitment to safe and responsible innovation in pain management.
“Addressing the challenges associated with pain requires collaboration across sectors,” Maglaris added. “We are grateful for the experience and commitment of our directors and advisors as we advance CYT-1010 through clinical development.”
About Cytogel
Cytogel Pharma is a clinical-stage biopharmaceutical company developing endomorphin-based therapies for the treatment of pain. Its lead candidate, CYT-1010, is an investigational therapy in Phase 2 clinical development for acute postoperative pain. Cytogel is committed to advancing differentiated science through rigorous clinical research and developing potential new pain-management options for patients and healthcare providers.
For more information, visit www.cytogelpharma.com.
Disclosure
CYT-1010 is an investigational new drug and has not been approved by the FDA or any regulatory body for use in humans or animals. This release contains forward-looking information about CYT-1010 and a potential new indication for the treatment of patients with moderate to severe post-operative pain via IV administration. Any potential benefits that may be implied by these statements involves substantial risks and uncertainties and actual results could differ materially from those expressed or implied by such statements, including, among other things, the possibility of unfavorable clinical trial results, unfavorable additional analyses of existing data; uncertainties regarding the commercial success of CYT-1010; the risk that regulatory authorities may require additional data or may deny approval altogether; rejection by the regulatory authorities of the design and results from our clinical studies; the possibility that any new drug applications for CYT-1010 may never be filed with regulatory authorities in any jurisdictions and, if filed, may never be approved in any jurisdictions or, if approved, could be severely limited by negative and restrictive labeling to the extent that commercial forecasts for CYT-1010 may never be realized.
Why it matters: As the opioid crisis continues to reshape how pain is treated, a novel therapy like CYT-1010 — backed by bipartisan public policy leaders — could offer a safer alternative for millions of post-surgical patients. The Phase 2 results due in early 2027 will be a critical test of whether this endomorphin-based approach can deliver on its promise.
Kimberly Weinrick
Cytogel Pharma
kweinrick@cytogelpharma.com
Visit us on social media:
LinkedIn
